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Abstract
Background: Peritoneal dialysis is an important type of renal replacement therapy for uremic patients. In peritoneal
dialysis, fluids fill in and flow out of the abdominal cavity three to five times per day. Usually, the fluid is packed in
a polyvinyl chloride (PVC) bag. Safety concerns have arisen over di-(2-ethylhexyl) phthalate, which is essential in the
formation of PVC materials. In 2011, the National Development and Reform Commission of China released a catalog
of industrial structural adjustments, mandating the elimination of PVC bags for intravenous infusion and food containers.
Although bags for peritoneal dialysis fluid were not included in the elimination list, several manufacturers began
to develop new materials for fluid bags. HUAREN peritoneal dialysis fluid consists of the same electrolytes and buffer
agent as in Baxter fluid, but is packed in bags that do not contain PVC. This multicenter randomized controlled
trial was designed to compare peritoneal dialysis fluid packed in non-PVC-containing and PVC-containing bags.
Further, the study sought to determine the proper dose of peritoneal dialysis fluid and the actual survival rates
of Chinese patients undergoing peritoneal dialysis.
Methods/Design: The study participants are adults undergoing continuous ambulatory peritoneal dialysis for
30 days to 6 months. All eligible patients are randomized (1:1) to peritoneal dialysis with Baxter and HUAREN
dialysis fluids (initial dose, 6 l/day), with dosages adjusted according to a unified protocol. The primary outcomes are
the 1-, 2-, 3-, 4-, and 5-year overall survival rates. Secondary outcome measures include technique survival rates,
reductions in estimated glomerular filtration rate, nutritional status, quality of life, cardiovascular events, medical
costs and drop-out rates. Safety outcome measures include adverse events, changes in vital signs and laboratory
parameters, peritonitis, allergies, and quality of products.
Discussion: This study is the first to evaluate the long-term safety and effectiveness of a non-PVC packed peritoneal
dialysis fluid. The effects of plasticizer on patient long-term survival will be determined. The characteristics of Chinese
patients undergoing peritoneal dialysis will be determined, including proper dose, technique survival rates, patient
survival rates, and medical costs.
Trial registration: Clinicaltrials.gov NCT01779557.
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Background
Peritoneal dialysis is a major type of renal replacement
therapy. Worldwide, up to about 200,000 patients, or
about 12 % of all patients with end-stage renal disease,
currently undergo peritoneal dialysis. This therapy in-
volves filling of the abdominal cavity and drainage of
peritoneal dialysis fluids three to five times per day, with
each patient requiring 6 to 10 liters of peritoneal dialysis
fluid per day. Dianeal® (Baxter Inc.) is the most widely
used commercially available peritoneal dialysis fluid in
China and has been used for many years. The dialysis fluid
is packed in a bag made of polyvinyl chloride (PVC). The
plasticizer most frequently added to PVC to improve its
flexibility is di-(2-ethylhexyl) phthalate (DEHP). However,
DEHP can be released by PVC materials because it is not
chemically bonded to the polymer. Moreover, DEHP can
be incorporated into the human body and be detected in
body fluids and tissues. It has been shown that DEHP is
toxic to the liver, testis, and other organs [1, 2], and that its
major metabolite, mono-(2-ethylhexyl) phthalate, is even
more toxic than DEHP. Use of this plasticizer has aroused
great concern regarding the safety of PVC materials [3, 4].
Many daily utensils contain plasticizer, which might be
harmful to human health [5–10]. Medical tubing and bags
made of PVC, such as bloodlines for hemodialysis and bags
for peritoneal dialysis fluids, might expose patients to con-
siderable amounts of plasticizer and its hydrolytic metabo-
lites. The safety of plasticizers in medical materials has
been evaluated by the USA, Japan, and the European
Union for more than 10 years. In 2011, the Chinese Na-
tional Development and Reform Commission released a
catalog of industrial structural adjustments [11], mandat-
ing the elimination of PVC bags for infusion and food
containers. Although bags for peritoneal dialysis fluids
were not included on that list, the presence of higher con-
centrations of DEHP in patients receiving continuous am-
bulatory peritoneal dialysis [12] has led manufacturers to
seek new materials for peritoneal dialysis bags. HUAREN
peritoneal dialysis fluid is a non-PVC packed Chinese
product that contains the same electrolytes and buffering
agent as Baxter fluid. Several studies have investigated
non-PVC peritoneal dialysis fluid products (e.g., bicaVera®,
balance®) [13, 14]. However, because the packaging mater-
ial is the only difference between HUAREN and Baxter
peritoneal dialysis fluids, a study comparing the two
should clearly show the effects of plasticizer.
The targeted small solute clearance for Asian patients is
Kt/V ≥ 1.7 [15], although other targets have been sug-
gested [16–19]. The proper dose required to attain this
goal may differ among populations, owing to differences
in race, ethnicity, and food consumption. A dosage of 8 l/
day is often used in Western populations, whereas the
dosage for Asians is usually 6 l/day. Our previous research
showed that an initial dose of 6 l/day could provide ad-
equate peritoneal dialysis for 48 weeks [20], but the proper
dosage afterwards remains unclear. The proper dosage for
Chinese patients receiving continuous ambulatory peri-
toneal dialysis is unclear, as are their mid- to long-term
survival rates. This study includes a protocol for adjusting
dosage based on each patient’s medical status. With a 5-
year follow-up period, the ‘proper’ dosage and ‘real’ situa-
tions of Chinese patients receiving continuous ambulatory
peritoneal dialysis can be determined.
Methods/Design
Study design
This is a prospective, multicenter, randomized controlled
trial with non-inferiority design. Patients will be ran-
domized to HUAREN or Baxter peritoneal dialysis fluid
(Fig. 1).
Patients
Male and female patients aged ≥18 years diagnosed with
end-stage renal disease who undergo continuous ambu-
latory peritoneal dialysis for 30 to 180 days are included.
Patients diagnosed with diabetic kidney disease have a
residual glomerular filtration rate of 3 to 15 ml/min [21],
whereas patients with other renal diseases have a re-
sidual glomerular filtration rate of 3 to 10 ml/min.
Fig. 1 Study design. This is a randomized controlled trial. The eligible patients will be randomly allocated to two groups, Baxter group or HUAREN
group. Patients will use Baxter or HUAREN peritoneal dialysis fluid for 5 years. The outcomes will be analyzed and compared. ESRD, end-stage renal
disease; PD, peritoneal dialysis
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All patients must provide written informed consent be-
fore undergoing any study-related procedures.
Patients are excluded if: they have acute renal failure;
are candidates for kidney transplantation; are undergoing
hemodialysis; have an exit site infection, tunnel infection
or peritonitis according to Peritoneal Dialysis Standard
Operating Procedure [22]; are anti-HIV positive; are aller-
gic to any component of dialysis fluids; have a systemic in-
fection, malignancy, liver cirrhosis, severe congestive heart
failure, anemia (hemoglobin <80 g/l), malnutrition (albu-
min <28 g/l), refractory hypertension, high peritoneal
transportation (D/PCr > 0.81); or are pregnant or lactating.
Patients with poor compliance or a history of alcoholism
or drug abuse are also excluded.
Patients are being recruited from 50 peritoneal dialysis
centers throughout China. The study protocol was ap-
proved by the ethics committee of each center (Additional
file 1) and is conducted according to the Declaration of
Helsinki [23] and the Good Clinical Practices guide-
lines of the China Food and Drug Administration [24].
The study has been registered at www.clinicaltrials.gov,
number NCT01779557.
Randomization
Patients are centrally randomized 1:1 to HUAREN or Bax-
ter peritoneal dialysis fluid, using a randomization chart
generated by a biometrician blinded to clinical treatment.
Physicians and nurses are also blinded to the randomization
process, and each patient can be randomized only once. All




Patients randomized to the HUAREN group will receive
HUAREN dialysis fluid, a medical product that has been
available in China for years. All the ingredients of HUA-
REN peritoneal dialysis fluid are identical to those of
Baxter peritoneal dialysis fluid except for the packaging
material, in that HUAREN peritoneal dialysis fluids are
packed in bags made of non-PVC materials.
Baxter group
Patients randomized to the Baxter group will receive Bax-
ter Dianeal dialysis fluid. This product contains 1.5 % dex-
trose as an osmotic agent and 40 mmol/l lactate as a
buffering agent. The pH of this dialysis fluid is 5.5, and
total osmotic pressure is 346 mOsm/kg. Other ingredients
include 1.75 mmol/l Ca2+, 0.25 mmol/l Mg2+, 132 mmol/l
Na+, and 96 mmol/l Cl−. Baxter dialysis fluids are packed
in bags made of PVC materials.
During the screening period, all patients receive HUA-
REN dialysis fluid. After randomization, patients receive
the allocated dialysis fluid.
Protocol for dosage adjustment
The initial dose in the two groups is 6 l/day, allowing
three fluid exchanges. If Kt/Vtotal < 1.7, the dose is in-
creased to 8 l/day, allowing four fluid exchanges. If Kt/V
total is ≥ 1.7, but with volume overload (e.g., heart failure,
serous cavity effusion, moderate or severe edema), salt
and water intake is restricted and diuresis starts. If this is
insufficient, dextrose concentration is increased to 2.5 %
or 4.25 %, depending on clinical demands. If a patient’s
condition does not improve after administration of >6 l of
fluid containing 2.5 % dextrose or >2 l of fluid containing
4.25 % dextrose, the dosage is increased to 8 l/day.
If Kt/V total ≥ 1.7 and the patient is euvolemic, but with
uremic manifestations, such as nausea, vomiting, or prur-
itus, the dose is increased from 6 l/day to 8 l/day.
Dosage changes from 8 l/day to 10 l/day should follow
the same principle and procedure (Fig. 2).
Outcomes
The primary outcome measure is patient survival rates at
1, 2, 3, 4, and 5 years. The secondary outcome measures
include peritoneal dialysis technique survival rates of 1, 2,
3, 4, and 5 years; estimated decline in glomerular filtration
rate, nutritional status (represented as serum albumin and
Subjective Global Assessment Score [25]), quality of life
(described by the 36-Item Short-Form Health Survey
[26]), cardiovascular events (cardiac sudden death, myo-
cardial infarction, severe arrhythmia, carotid plaque, heart
failure, cardiovascular intervention, coronary heart disease
without myocardial infarction, stroke or transient ische-
mic attack, peripheral artery disease), increments of dialy-
sis dosage from baseline to the end, and drop-out rates.
Medical costs are also recorded.
Safety evaluations include adverse events and severe ad-
verse events, marked changes of vital signs and laboratory
test results, peritonitis (infectious or chemical), allergy to
ingredients of peritoneal dialysis fluids and materials of
bags and tubing, and quality of dialysis product. Evaluation
of product quality includes the transparency of fluid bags,
the tightness of connections, and the legibility of labels and
texts on packaging.
Sample size
The sample size is based on both Chinese facilities con-
taining large numbers of patients [27–31] and the Chinese
National Renal Data System [32], consisting of smaller
units. We have estimated that the mean 5-year survival
rate of patients using Baxter dialysis fluid is about 50 %,
with a hazard ratio of 1.31. If the recruitment lasts 2 years
and the observation 5 years, with β = 0.8, a one-sided α for
the t test = 0.025, and 15 % censored data in each group,
310 patients per group will be needed. With a 20 % drop-
out rate, 750 patients should be enrolled in this study.
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Statistics
The primary analysis population is the per-protocol set,
consisting of randomized patients with baseline data and
data on primary outcome measures, as well as good com-
pliance. This population includes patients who quit the
study because of lack of drug effectiveness. The secondary
analysis population is the full analysis set according to the
intention-to-treat principle; this population includes all
randomized patients who receive therapy at least once, re-
gardless of whether they adhere to the protocol or provide
a complete dataset. Patients who never receive therapy are
excluded. Patients with missing data are included, with ad-
jacent data carried forward to the missing data. The full
analysis set population is consistent throughout the entire
study. The safety analysis population is the safety set, which
includes all patients who receive therapy at least once.
Patient survival rates are analyzed by constructing a Cox
regression model that includes multiple variables, such as
baseline glomerular filtration rate, severity of disease, age,
and treatment group. A non-inferiority test is determined
by computing the 95 % confidence interval of the hazard
ratio. The same method is used to analyze technique sur-
vival rates. Decline in estimated glomerular filtration rate
is analyzed by the Wilcoxon rank-sum test. Nutritional
status and quality-of-life score are analyzed by analysis of
covariance. Rates of cardiovascular events and patient
drop-out are analyzed by the Cochran–Mantel–Haenszel
χ2 test. Increments of dialysis dosage from baseline to the
end of treatment are analyzed by constructing a mixed
model. Medical costs are compared by t test or analysis of
variance. Adverse events and severe adverse events are
categorized according to terminology in the Medical Dic-
tionary for Regulatory Activities. Adverse events, severe
adverse events, peritonitis, and allergies are compared by
the χ2 test or Fisher’s exact test. Product quality is evalu-
ated by nonparametric tests.
Discussion
Peritoneal dialysis has become one of the most import-
ant renal replacement therapies. Because peritoneal dia-
lysis is equivalent to or better than hemodialysis in the
early stage [33], as well as its other advantages, including
lower cost, greater convenience, better preservation of
residual renal function, and greater ability to accommo-
date more patients with end-stage renal disease because
of its lower infrastructure requirements [34], the use of
peritoneal dialysis is continuously expanding worldwide,
especially in developing countries [35]. At present, about
12 % of patients with end-stage renal disease worldwide
are treated with peritoneal dialysis. In China, about 16 %
Fig. 2 Dosage adjustment protocol. The initial dosage is 6 l/day; then the solute clearance, water removal, and clinical manifestation are evaluated. If Kt/V
< 1.7, dosage should be increased. If there is a volume overload, salt and water intake, diuretics, and dextrose concentration should be modified before
changing dosage. When the dosage is≥ 12 l/day and Kt/V< 1.7, the treatment adaptation fails. Physicians should be flexible in choosing optimal therapies
to protect patients from life-threatening circumstances. The Kt/V and creatinine clearance rate should be re-evaluated 2 weeks after each
patient’s situation stabilizes
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of patients with end-stage renal disease, or about 50,000 in-
dividuals, undergo peritoneal dialysis, and the number is
increasing dramatically [32]. A combination of increasing
affluence, urbanization, changing lifestyles, and high rates
of diabetes have all been associated with a dramatic in-
crease in the numbers of patients who require dialysis [36].
According to data from the National Bureau of Statis-
tics of China, the population of mainland China at the
end of 2013 was 1,360,720,000 individuals [37], and the
prevalence of chronic kidney disease was about 10.8 %
[38]. Thus, over 140 million people in China are estimated
to have chronic kidney disease. Diabetes, a major cause of
end-stage renal disease, has a prevalence of 11.6 %, affect-
ing about 120 million persons [39]. Hypertension, another
major cause of end-stage renal disease, has a much higher
prevalence, of 26.6 %, in Chinese adults, affecting an esti-
mated 360 million people [40], and a newly published sur-
vey found that the prevalence was much higher [41]. The
increasing numbers of patients with these causes of end-
stage renal disease make chronic kidney disease a public
health problem. Because many patients in China cannot
afford treatment for end-stage renal disease, the Chinese
government has launched a series of new policies for
the use of peritoneal dialysis and extension of medical
insurance coverage. Efforts are underway to improve
peritoneal dialysis techniques and products to treat
more uremic patients.
In China, the appropriate peritoneal dialysis dosage re-
mains unclear. Western patients are often treated with 8 l/
day, whereas 6 l/day is believed sufficient for incident peri-
toneal dialysis in Asian patients. Chinese patients differ
ethnically from patients in Western countries. Although
Chinese patients are similar ethnically to patients in Hong
Kong and Japan, their economic status, which is important
for peritoneal dialysis use, is quite different. Our previous
study showed that 6 l/day was sufficient for adequate peri-
toneal dialysis in Chinese patients, although a 48-week
follow-up showed continuous decline in Kt/V and creatin-
ine clearance rate [20]. Further decreases in Kt/V and
creatinine clearance rate would necessitate increases in
peritoneal dialysis dosage. In this study, the observation
period is 5 years. Thus, dosage could not be fixed at 6
or 8 l/day; rather, it would have to be changed accord-
ing to clinical situations. The trial described here would
therefore be a study of the effectiveness, not the effi-
cacy, of peritoneal dialysis [42]. The dosage adjustment
protocol in this study is almost the same as that in rou-
tine clinical circumstances.
This study compares two types of peritoneal dialysis fluid,
one packed in PVC and the other in non-PVC materials. It
is known that PVC has deleterious effects on human health,
owing to the added plasticizer (i.e., DEHP), although the
significance of its toxicity may be exaggerated [43, 44],
Moreover, an as-yet-unknown toxicity may manifest during
long-term usage. The toxicity of the plasticizer has been
confirmed [45, 46], limiting the usage in some countries of
PVC materials in medical devices and food and drug uten-
sils [47]. The Chinese National Development and Reform
Committee released a catalog of industrial structural adjust-
ments in 2011, although peritoneal dialysis fluids were ex-
cluded from the list [48]. However, use of the plasticizer
remains a public and medical concern. This is not the first
trial to compare PVC and non-PVC materials in peritoneal
dialysis, but it is the first long-term head-to-head compari-
son of peritoneal dialysis fluids packed in PVC and non-
PVC materials. Studies have compared the traditional PVC
packed dialysis fluid Dianeal® and non-PVC packed peri-
toneal dialysis fluids, but these fluids have many differences
other than their packaging, including pH and buffering
agent. The two types of peritoneal dialysis fluid in this trial
have the same pH, buffer, and osmotic agents, with only
the packaging material differing, in that Dianeal® is packed
in PVC and HUAREN dialysis fluid in non-PVC bags.
This study may also reveal some of the disadvantages of
non-PVC material. For example, this material may be stiff
and fragile, and may be prone to leakage when used for
peritoneal dialysis, resulting in peritonitis. The PVC pack-
aging has better elasticity, flexibility, and durability, mak-
ing it useful as a liquid container. In a large country, such
as China, peritoneal dialysis fluids travel a great distance
to reach patients’ homes. Climate, temperature, and phys-
ical abrasion all challenge the packaging of dialysis fluids.
Transportation of peritoneal dialysis fluids to patients in
the far north of China is especially long and difficult and
may have deleterious effects if the packaging is not dur-
able. Thus, it remains unclear whether the use of non-
PVC packed peritoneal dialysis fluids is feasible in China.
This study also involves some social and economic
aspects, including patient quality of life, the quality of
dialysis products, and medical costs. This study reflects
real-life situations, making it more relevant to setting
policy and evaluating the effects of treatment. This
study, a type of comparative effectiveness research, may
provide useful information about Chinese peritoneal
dialysis patients and suggest reasonable policies to the
Chinese government. China is undergoing comprehensive
reform, including healthcare reform. Three years ago,
former premier Wen Jiabao announced that the Chinese
government would fully introduce social insurance against
uremia. Mr Chen Zhu, former leader of the Chinese Minis-
try of Health, put forward a series of healthcare policies to
improve uremia care and to use domestic dialysis products
[49]. HUAREN peritoneal dialysis fluid is a Chinese do-
mestic non-PVC packed dialysis product that has been
on the market for years. Thus, the results of this non-
inferiority trial may enable the government to make a
decision. If the non-PVC material is not inferior to
PVC material, HUAREN should be further developed.
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If, however, the non-PVC material is inferior to PVC, the
legal situation of PVC should be clarified. Regardless of the
results, additional well-designed randomized controlled tri-
als and cohort studies will be needed to obtain additional
high-level evidence about Chinese peritoneal dialysis prod-
ucts. ‘To resolve our own problems with domestic prod-
ucts’ is not only a slogan but also a useful method for
developing peritoneal dialysis in a large developing country
like China. Moreover, it may provide experience that can
be used by other developing countries. It should be noted
that we exclude patients who are keen to receive a trans-
plant quickly, because these patients are usually not the
healthiest, and the transplantation incidence is often not in
accordance with epidemiological rules. This may cause
some bias, which we should pay attention to when translat-
ing the results of the study to other peritoneal dialysis
populations.
Trial status
This study is currently recruiting participants.
Additional file
Additional file 1: The ethical bodies that approved the study in the
various centers. This file includes the names of all the ethical bodies who
approved the study protocol in every center participating in this clinical trial.
(DOC 34 kb)
Abbreviations
DEHP: di-(2-ethylhexyl) phthalate; PVC: polyvinyl chloride.
Competing interests
The authors declare no financial or nonfinancial competing interests in relation
to this manuscript.
Authors’ contributions
JZ drafted the paper, participated in the design of the study, and assisted in
multicenter cooperation. XC assisted in patient recruitment and protocol revision.
HL was responsible for the dosage adjustment protocol and participated in the
study design. ZN, YH, and MC participated in study design and revision of the
protocol. HZ participated in revision of the study protocol. XC was the principal
investigator and was in charge of organizing the study group and guiding the
study process; she was the initial developer of this study and participated
in critical revision of the manuscript. All authors read and approved the
final manuscript.
Acknowledgements
This study is funded by the National Key Technologies R&D Program during
the Twelfth Five-year Plan Period (2011BAI10B00) and the Foundation for
National Clinical Research Center (2015BAI12B06, 2013BAI09B05). The funding
sources will not play any role in any aspect of this study design.
Author details
1Department of Nephrology, Chinese PLA General Hospital, Chinese PLA
Institute of Nephrology, State Key Laboratory of Kidney Diseases, National
Clinical Research Center for Kidney Diseases, 28 Fuxing RoadHaidian District,
Beijing 100853, China. 2Department of Nephrology, First Affiliated Hospital of
Dalian Medical University, 222 Zhongshan Road, Zhongshan District, Dalian,
Liaoning, Province 116011, China. 3Renal Division, Renji Hospital, Shanghai
Jiao Tong University School of Medicine, 145 Shandongzhong RoadHuangpu
District, Shanghai 200127, China. 4Department of Nephrology, Daping
Hospital, Third Military Medical University, 10 Changjiangzhilu
DapingYuzhong District, Chongqing 400042, China. 5Department of
Nephrology, General Hospital of Ningxia Medical University, 804 Shenglinan
Road, Xingqing District, Yinchuan, Ningxia, Hui Autonomous Region 750004,
China. 6Department of Nephrology, General Hospital of Shenyang Military
Command, 83 Wenhua Road, Shenhe District, Shenyang, Liaoning, Province
110016, China.
Received: 17 February 2015 Accepted: 17 December 2015
References
1. du Bang Y, Lee IK, Lee BM. Toxicological characterization of phthalic acid.
Toxicol Res. 2011;27:191–203.
2. Wahl HG, Hong Q, Hildenbrand S, Risler T, Luft D, Liebich H.
4-Heptanone is a metabolite of the plasticizer di(2-ethylhexyl)
phthalate (DEHP) in haemodialysis patients. Nephrol Dial Transplant.
2004;19:2576–83.
3. Fischer FP, Machleidt C, Rettenmeier AW, Kuhlmann U, Mettang T.
Plasticizers and inhibition of leukocyte function in vitro. Perit Dial Int.
1998;18:620–5.
4. Roth Z, Hadas R, Maor Y, Kalo D. In vivo model to examine the long-lasting
effects of acute di-(2-ethylhexyl) phthalate (DEHP) exposure on ovarian
function in bovine. Reprod Fertil Dev. 2014;27:174.
5. Duty SM, Ackerman RM, Calafat AM, Hauser R. Personal care product use
predicts urinary concentrations of some phthalate monoesters. Environ
Health Perspec. 2005;113:1530–5.
6. Just AC, Adibi JJ, Rundle AG, Calafat AM, Camann DE, Hauser R, et al.
Urinary and air phthalate concentrations and self-reported use of personal
care products among minority pregnant women in New York City. J Expo
Sci Environ Epidemiol. 2010;20:625–33.
7. Romero-Franco M, Hernandez-Ramirez RU, Calafat AM, Cebrian ME, Needham
LL, Teitelbaum S, et al. Personal care product use and urinary levels of
phthalate metabolites in Mexican women. Environ Int. 2011;37:867–71.
8. Janjua NR, Frederiksen H, Skakkebaek NE, Wulf HC, Andersson AM. Urinary
excretion of phthalates and paraben after repeated whole-body topical
application in humans. Int J Androl. 2008;31:118–30.
9. Buckley JP, Palmieri RT, Matuszewski JM, Herring AH, Baird DD, Hartmann
KE, et al. Consumer product exposures associated with urinary phthalate
levels in pregnant women. J Expo Sci Environ Epidemiol. 2012;22:468–75.
10. Sathyanarayana S, Karr CJ, Lozano P, Brown E, Calafat AM, Liu F, et al. Baby
care products: possible sources of infant phthalate exposure. Pediatrics.
2008;121:e260–8.
11. The official website of Chinese National Development and Reform
Commission: http://www.sdpc.gov.cn/zcfb/zcfbl/201104/t20110426_
408008.html.
12. Mettang T, Thomas S, Kiefer T, Fischer FP, Kuhlmann U, Wodarz R, et al. The
fate of leached di(2-ethylhexyl)phthalate in patients undergoing CAPD
treatment. Perit Dial Int. 1996;16:58–62.
13. Alscher DM, Pauli-Magnus C, Kirchgessner J, Kuhlmann U, Mettang T. A new
lactate-based, plasticizer-free, neutral peritoneal dialysis fluid provided in a
two-compartment system: effect on peripheral leukocyte function. Nephron.
2000;86:62–9.
14. Mettang T, Pauli-Magnus C, Alscher DM, Kirchgessner J, Wodarz R,
Rettenmeier AW, et al. Influence of plasticizer-free CAPD bags and tubings
on serum, urine, and dialysate levels of phthalic acid esters in CAPD
patients. Perit Dial Int. 2000;20:80–4.
15. Lam MF, Tang C, Wong AK, Tong KL, Yu AW, Li CS, et al. ASPD: a prospective
study of adequacy in Asian patients on long term, small volume, continuous
ambulatory peritoneal dialysis. Perit Dial Int. 2006;26:466–74.
16. Churchill D. Implications of the Canada–USA (CANUSA) study of the
adequacy of dialysis on peritoneal dialysis schedule. Nephrol Dial
Transplant. 1998;13:s158–63.
17. CANADA–USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of
dialysis and nutrition in continuous peritoneal dialysis: association with
clinical outcomes. J Am Soc Nephrol. 1996;7:198–207.
18. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al.
Effects of increased peritoneal clearances on mortality rates in peritoneal
dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc
Nephrol. 2002;13:1307–20.
19. Paniagua R, Amato D, Vonesh E, Guo A, Mujais S. Health-related quality of
life predicts outcomes but is not affected by peritoneal clearance: the
ADEMEX trial. Kidney Int. 2005;67:1093–104.
Zhou et al. Trials  (2015) 16:592 Page 6 of 7
20. Zhou JH, Ni ZH, Mei CL, Yu XQ, Liu FY, Miao LN, et al. Efficacy and safety of
Changfu peritoneal dialysis solution: a multi-center prospective randomized
controlled trial. Chin Med J (Engl). 2013;126:4204–9.
21. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes
and CKD: 2012 update. Am J Kidney Dis. 2012;60:850–86.
22. Chen XM. Complications of peritoneal dialysis. In: Peritoneal Dialysis
Standard Operating Procedure (SOP). Beijing: Chinese People’s Military
Medical Press; 2010. p. 72–95.
23. WMA Declaration of Helsinki. Ethical principles for medical research
involving human subjects. http://www.wma.net/en/30publications/
10policies/b3/index.html.
24. Good Clinical Practice of China Food and Drug Administration. http://www.
sda.gov.cn/WS01/CL0053/24473.html.
25. K/DOQI, National Kidney Foundation. Clinical practice guidelines for
nutrition in chronic renal failure. Am J Kidney Dis. 2000;35:S1–140.
26. Ware JEJ, Sherbourne CD. The MOS 36-Item Short-Form Health Survey
(SF-36): I. conceptual framework and item selection. Med Care. 1992;30:
473–83.
27. Xu Y, Dong J, Zuo L. Is frequency of patient–physician clinic contact
important in peritoneal dialysis patients? Perit Dial Int. 2009;29:S83–9.
28. Fang W, Qian J, Lin A, Rowaie F, Ni Z, Yao Q, et al. Comparison of peritoneal
dialysis practice patterns and outcomes between a Canadian and a Chinese
centre. Nephrol Dial Transplant. 2008;23:4021–8.
29. Fang W, Ni Z, Qian J. Key factors for a high-quality peritoneal dialysis
program – the role of the PD team and continuous quality improvement.
Perit Dial Int. 2014;34:S35–42.
30. Zhang X, Shou Z, Chen Z, Xu Y, Han F, Yin X, et al. The role of an
integrated care model for kidney disease in the development of
peritoneal dialysis: a single-center experience in China. Perit Dial Int.
2014;34:S55–8.
31. Zhang F, Liu H, Gong X, Liu F, Peng Y, Cheng M, et al. Risk factors for
mortality in Chinese patients on continuous ambulatory peritoneal dialysis.
Perit Dial Int. 2015;35:199–205.
32. Chen XM, CNRDS group. The annual report of the Chinese National Renal
Data System. Beijing: Chinese National Medical Quality Control Center for
Kidney Diseases; 2013.
33. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. Mortality studies comparing
peritoneal dialysis and hemodialysis: what do they tell us? Kidney Int.
2006;103:s3–11.
34. Nayak KS, Prabhu MV, Sinoj KA, Subhramanyam SV, Sridhar G. Peritoneal
dialysis in developing countries. Contrib Nephrol. 2009;163:270–7.
35. Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal
dialysis. J Am Soc Nephrol. 2012;23:533–44.
36. Blake PG, Wilkie M. Peritoneal dialysis in China: a story of growth and innovation.
Perit Dial Int. 2014;34:s27–8.
37. Data from the official website of National Bureau of Statistics of the
People’s Republic of China. http://www.stats.gov.cn.
38. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. Prevalence of
chronic kidney disease in China: a cross-sectional survey. Lancet.
2012;379:815–22.
39. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of
diabetes in Chinese adults. JAMA. 2010;2013(310):948–59.
40. Gao Y, Chen G, Tian H, Lin L, Lu J, Weng J, et al. Prevalence of hypertension
in China: a cross-sectional study. PLoS One. 2013;8, e65938.
41. Wang J, Zhang L, Wang F, Liu L, Wang H. China National Survey of Chronic
Kidney Disease Working Group. Prevalence, awareness, treatment, and
control of hypertension in China: results from a national survey. Am J
Hypertens. 2014;27:1355–61.
42. Last J, Spasoff RA, Harris S. A Dictionary of Epidemiology. Oxford: Oxford
University Press; 2001.
43. Narikiyo T, Mori Y, Somyo Y, Nakamoto M. Is plasticizer toxic to peritoneal
mesothelial cells? Adv Perit Dial. 2007;23:51–6.
44. US Food and Drug Administration. Safety Assessment of Di
(2-ethylhexyl)phthalate (DEHP) Released from PVC Medical Devices.
2001. http://www.fda.gov/downloads/MedicalDevices/
DeviceRegulationandGuidance/GuidanceDocuments/UCM080457.pdf.
45. Braun JM, Sathyanarayana S, Hauser R. Phthalate exposure and children’s
health. Curr Opin Pediatr. 2013;25:247–54.
46. Erythropel HC, Maric M, Nicell JA, Leask RL, Yargeau V. Leaching of
the plasticizer di(2-ethylhexyl)phthalate (DEHP) from plastic containers
and the question of human exposure. Appl Microbiol Biotechnol.
2014;98:9967–81.
47. US Department of Health and Human Services Food and Drug Administration
Center for Drug Evaluation and Research (CDER). Guidance for Industry
Limiting the Use of Certain Phthalates as Excipients in CDER-Regulated
Products. 2012. http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM294086.pdf.
48. Chinese National Development and Reform Commission. Beijing: Catalogue
of Industrial Structure adjustment; 2011.
49. Chen Z. Good news for end stage renal disease patients. Chin Med J (Engl).
2013;126:4203.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Zhou et al. Trials  (2015) 16:592 Page 7 of 7
